Tactile Systems Technology, Inc.
Rank #10Capital ReturnTCMD · Nasdaq · Healthcare
Tactile Systems Technology, Inc. (TCMD) — Rank #10 by gross profitability (GP/assets 0.89) · ROE 8.5% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001027838 · all metrics point-in-time as of the filing date.
About
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.
Show moreShow less
It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc.
was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MN
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- tactilemedical.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-17 | 2024-12-31filed 2025-02-18 | 2023-12-31filed 2024-02-20 | 2022-12-31filed 2023-02-21 |
|---|---|---|---|---|
| Revenue | 329.5 | 293.0 | 274.4 | 246.8 |
| Revenue growth (YoY) | 12.5% | 6.8% | 11.2% | 18.6% |
| Cost of revenue | 79.4 | 76.3 | 79.3 | 70.8 |
| Gross profit | 250.1 | 216.7 | 195.1 | 176.0 |
| Gross margin | 75.9% | 74.0% | 71.1% | 71.3% |
| Research & development | 8.5 | 8.8 | 7.8 | 7.1 |
| Operating income | 29.3 | 22.2 | 18.0 | (12.8) |
| Operating margin | 8.9% | 7.6% | 6.6% | -5.2% |
| Interest income | 3.1 | 3.4 | — | — |
| Pre-tax income | 31.3 | 23.5 | 15.8 | (15.5) |
| Income tax expense | 12.3 | 6.5 | (12.7) | 2.4 |
| Net income | 19.1 | 17.0 | 28.5 | (17.9) |
| Net margin | 5.8% | 5.8% | 10.4% | -7.2% |
| EPS (basic) | $0.83 | $0.71 | $1.24 | -$0.89 |
| EPS (diluted) | $0.82 | $0.70 | $1.23 | -$0.89 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?